Therapeutic Area: Psychiatry/Psychology Product Name: Senstend
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Wanbang Biopharmaceuticals
Deal Size: $4.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement December 02, 2020
Under the License Agreement Regent Pacific is now entitled to receive a payment of approximately HK$6.24 million from Wanbang Pharmaceutical, which is payable within 30 business days. NMPA will now formally review Senstend™ for Clinical Trial Approval.